Intraarterial Thrombolysis And Endovascular Treatment is Safe and Effective In Patients With Ischemic Stroke Due To Dissection (P5.159)
Citation Manager Formats
Make Comment
See Comments

Abstract
OBJECTIVE: To examine the safety and efficacy of intraarterial and endovascular treatment for acute ischemic stroke (AIS) due to dissection. BACKGROUND: Carotid and vertebral artery dissection should not be considered a contraindication for intravenous tPA treatment. Few studies report safety and efficacy of intraarterial thrombolysis or endovascular treatment for dissection. DESIGN/METHODS: We studied consecutive admissions with AIS to our Comprehensive Stroke Center from 2012-2013 who received intraarterial thrombolysis or an endovascular procedure (“aggressive therapy”). We examined differences in adverse events, defined as in-hospital death and symptomatic ICH (sICH), and favorable outcome, defined as Modified Rankin Score (mRS) ≤2 at discharge and 3 months, for AIS patients who presented with mechanism of dissection vs. other cause. RESULTS: Of 1,320 patients with AIS, 173 patients received aggressive therapy and comprise our study population: 15 with dissection (8.7[percnt]: 11 carotid, 4 vertebral) and 158 without dissection (91.3[percnt]). Stroke severity was similar with vs. without dissection (mean NIHSS: 15.4 vs. 17.2, p=0.29). There were no differences in adverse event rates for patients presenting with vs. without dissection (sICH: 0[percnt] vs. 8.2[percnt], p=0.61; mortality: 20.0[percnt] vs. 18.3[percnt], p=1.0). Notably, no AIS patients with dissection receiving aggressive therapy developed a sICH. There were also no differences in favorable outcome for patients presenting with vs. without dissection (discharge mRS ≤2: 26.7[percnt] vs. 20.4[percnt], p=0.52; 3 month mRS ≤2: 58.3[percnt] vs. 45.1[percnt], p=0.38). There were 3 deaths in patients with dissection: one death resulted from occlusion of a stent placed to treat stenosis caused by dissection. CONCLUSIONS: Aggressive therapy, including intraarterial thrombolysis and endovascular treatment, appears to be as safe and effective when used in patients with ischemic stroke due to dissection as in AIS patients with other causes. It would be difficult to create an ethical randomized trial to evaluate aggressive therapy in this patient population.
Disclosure: Dr. Jensen has nothing to disclose. Dr. Wagner has received personal compensation for activities with Genentech, Inc. Dr. Salottolo has nothing to disclose. Dr. Loy has nothing to disclose. Dr. Bar-Or has nothing to disclose.
Wednesday, April 22 2015, 2:00 pm-6:30 pm
- Copyright © 2015 by AAN Enterprises, Inc.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
- No related articles found.